Biogen (BIIB) stock dips as the company updates Phase 2 trial data for diranersen, an Alzheimer’s drug developed with Ionis ...

An experimental drug might help slow early Alzheimer's disease in a markedly different way than current treatments — by ...

Eplontersen’s failure in transthyretin-mediated amyloidosis cardiomyopathy caught Wall Street analysts by surprise and ...

Biogen and Ionis have revealed the first clinical results with tau-targeting Alzheimer's drug candidate diranersen, showing ...

The Swiss pharmaceutical giant told patient groups tominersen didn't delay disease progression in one trial, while a study of ...

Biogen (BIIB) stock falls as latest mid-stage trial data for Alzheimer’s drug diranersen developed with Ionis Pharmaceuticals ...

By Raechel Thankam Job July 9 (Reuters) - AstraZeneca shares tumbled on Thursday after the company said its nerve disease ...

July 9 (Reuters) - AstraZeneca said on Thursday its nerve disease drug Wainua, made in partnership with U.S.-based Ionis, ...

AstraZeneca and Ionis reported a notable trial failure Thursday in a heart disease that's become an increasingly competitive ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the first participant has been dosed in the Phase 1-2 ASCEND study of ION337, an investigational RNA-targeted medicine for people living ...

The drug trial for a rare type of heart disease showed the treatment was generally well tolerated but it did not work than a ...

The study provides the clearest evidence yet that medicines like BIIB080 might improve cognition, but leaves unclear why ...